Entreprises Auvergne-Rhône-Alpes, SPCCT, Spectral Photon Counting CT, HCL

The SPCCT project aims to develop and validate a new quantitative and analytical in vivo imaging technology by combining Spectral Photon Counting CT (SPCCT) and contrast agents. This technology is designed to provide accurate and early detection, characterization, and monitoring of neurovascular and cardiovascular diseases.

Spectral Photon Counting CT is an advanced imaging technique that offers improved contrast and spatial resolution compared to traditional CT scans. By combining this technology with contrast agents, the SPCCT project seeks to enhance the capabilities of medical imaging for diagnosing and monitoring diseases affecting the neurovascular and cardiovascular systems.

The primary objectives of the SPCCT project include:

Early Detection: The technology aims to enable early detection of diseases, allowing for timely intervention and treatment.

Accurate Characterization: SPCCT, in conjunction with contrast agents, aims to provide detailed and accurate characterization of the conditions affecting the neurovascular and cardiovascular systems.

Monitoring Progression: The technology is expected to facilitate continuous monitoring of disease progression, providing valuable information for personalized treatment plans.

Widespread Accessibility: The project emphasizes the development of a technology that is widely accessible, ensuring that its benefits can reach a broader population.

In summary, the SPCCT project represents an innovative approach to medical imaging, leveraging advanced technologies to improve diagnostic capabilities in the field of neurovascular and cardiovascular diseases.